Thermo Fisher Scientific Issues $3.76 Billion in Senior Notes

Details

issued $3.76 billion in senior notes through a public offering. The notes consist of $1 billion of 4.215% Senior Notes due 2031, $750 million of 4.550% Senior Notes due 2033, $1.3 billion of 4.902% Senior Notes due 2036, and $750 million of 5.546% Senior Notes due 2046. The company intends to use the net proceeds from the sale to pay a portion of the cash consideration for the acquisition of Clario Holdings, Inc., with the remainder potentially used for general corporate purposes. The notes are subject to certain redemption provisions and are rated investment grade by major credit rating agencies.

Items reported

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is a world-leading biotechnology company that provides essential tools and services for life sciences, biotechnology, pharmaceutical, and healthcare industries. Renowned for its extensive portfolio, the company specializes in offering innovative laboratory products, analytical instruments, and software solutions critical for research, diagnostics, and clinical applications. Thermo Fisher enables scientists to perform complex experiments with cutting-edge technology, from DNA sequencing and cell analysis to clinical diagnostics and specialty chemicals. Serving a vast array of sectors, the company impacts fields such as diagnostics, genetic engineering, and environmental monitoring. Its strategic acquisitions and collaborations strengthen its market presence, making it a go-to partner for scientific advancements and innovation. With operations spanning over 50 countries, Thermo Fisher plays a pivotal role in driving scientific discovery and improving health outcomes globally.